Literature DB >> 32015997

Epigallocatechin gallate in multiple system atrophy (PROMESA).

Kurt A Jellinger1.   

Abstract

Entities:  

Year:  2019        PMID： 32015997      PMCID： PMC6976410          DOI： 10.21037/atm.2019.11.141

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  24 in total

Review 1.  Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations.

Authors:  Benjamin Dehay; Mathieu Bourdenx; Philippe Gorry; Serge Przedborski; Miquel Vila; Stephane Hunot; Andrew Singleton; C Warren Olanow; Kalpana M Merchant; Erwan Bezard; Gregory A Petsko; Wassilios G Meissner
Journal:  Lancet Neurol       Date:  2015-06-03       Impact factor: 44.182

2.  Expanding the spectrum of neuronal pathology in multiple system atrophy.

Authors:  Matthew D Cykowski; Elizabeth A Coon; Suzanne Z Powell; Sarah M Jenkins; Eduardo E Benarroch; Phillip A Low; Ann M Schmeichel; Joseph E Parisi
Journal:  Brain       Date:  2015-05-16       Impact factor: 13.501

Review 3.  Recent advances in neuropathology, biomarkers and therapeutic approach of multiple system atrophy.

Authors:  Shunsuke Koga; Dennis W Dickson
Journal:  J Neurol Neurosurg Psychiatry       Date:  2017-08-31       Impact factor: 10.154

4.  Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS).

Authors:  Gregor K Wenning; François Tison; Klaus Seppi; Cristina Sampaio; Anja Diem; Farid Yekhlef; Imad Ghorayeb; Fabienne Ory; Monique Galitzky; Tommaso Scaravilli; Maria Bozi; Carlo Colosimo; Sid Gilman; Clifford W Shults; Niall P Quinn; Olivier Rascol; Werner Poewe
Journal:  Mov Disord       Date:  2004-12       Impact factor: 10.338

Review 5.  Active immunization therapies for Parkinson's disease and multiple system atrophy.

Authors:  Achim Schneeberger; Lanay Tierney; Markus Mandler
Journal:  Mov Disord       Date:  2015-08-11       Impact factor: 10.338

6.  Second consensus statement on the diagnosis of multiple system atrophy.

Authors:  S Gilman; G K Wenning; P A Low; D J Brooks; C J Mathias; J Q Trojanowski; N W Wood; C Colosimo; A Dürr; C J Fowler; H Kaufmann; T Klockgether; A Lees; W Poewe; N Quinn; T Revesz; D Robertson; P Sandroni; K Seppi; M Vidailhet
Journal:  Neurology       Date:  2008-08-26       Impact factor: 9.910

7.  Intrathecal administration of autologous mesenchymal stem cells in multiple system atrophy.

Authors:  Wolfgang Singer; Allan B Dietz; Anita D Zeller; Tonette L Gehrking; James D Schmelzer; Ann M Schmeichel; Jade A Gehrking; Mariana D Suarez; David M Sletten; Karla V Minota Pacheco; Elizabeth A Coon; Paola Sandroni; Eduardo E Benarroch; Robert D Fealey; Joseph Y Matsumoto; James H Bower; Anhar Hassan; Andrew McKeon; Anthony J Windebank; Jay N Mandrekar; Phillip A Low
Journal:  Neurology       Date:  2019-05-31       Impact factor: 11.800

8.  Feasibility and Efficacy of Intra-Arterial Administration of Mesenchymal Stem Cells in an Animal Model of Double Toxin-Induced Multiple System Atrophy.

Authors:  Ha Na Kim; Dong Yeol Kim; Se Hee Oh; Hyung Sook Kim; Kyung Suk Kim; Phil Hyu Lee
Journal:  Stem Cells Transl Med       Date:  2017-03-13       Impact factor: 6.940

Review 9.  Like prions: the propagation of aggregated tau and α-synuclein in neurodegeneration.

Authors:  Michel Goedert; Masami Masuda-Suzukake; Benjamin Falcon
Journal:  Brain       Date:  2016-09-21       Impact factor: 13.501

Review 10.  Multiple System Atrophy: An Oligodendroglioneural Synucleinopathy1.

Authors:  Kurt A Jellinger
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.